Literature DB >> 8223667

In vitro activity of the new quinolone BAY y 3118 against anaerobic bacteria.

C E Nord1, A Lindmark, I Persson.   

Abstract

The in vitro activity of BAY y 3118 against anaerobic cocci, Propionibacterium acnes, Clostridium perfringens, Clostridium difficile, Bacteroides fragilis, other Bacteroides spp. and fusobacteria was determined by an agar dilution method. This activity was compared with that of ciprofloxacin, ofloxacin, piperacillin, cefoxitin, imipenem, clindamycin and metronidazole. BAY y 3118, imipenem, clindamycin and metronidazole were the most active agents tested. The in vitro activity of BAY y 3118 against anaerobic bacteria was superior to that of ciprofloxacin and ofloxacin.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8223667     DOI： 10.1007/bf01973648

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


  1 in total

1.  Antibiotic susceptibility of anaerobic bacteria with special reference to Bacteroides fragilis.

Authors:  K Dornbusch; C E Nord; B Olsson-Liljeqvist
Journal:  Scand J Infect Dis Suppl       Date:  1979
  1 in total
  7 in total

1.  In vitro activities of Y-688, a new 7-substituted fluoroquinolone, against anaerobic bacteria.

Authors:  A P MacGowan; K E Bowker; M Wootton; H A Holt; D S Reeves
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

2.  In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans.

Authors:  E J Goldstein; D M Citron; M Hudspeth; S Hunt Gerardo; C V Merriam
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

3.  Comparative in vitro activity of BAY Y 3118 with other fluoroquinolones.

Authors:  G Molinari; G C Schito
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 4.  Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.

Authors:  J A Balfour; H M Bryson; R N Brogden
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

5.  Comparative activities of eight quinolones against members of the Bacteroides fragilis group.

Authors:  M V Borobio; M Conejo; E Ramirez; A I Suarez; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

6.  Bay Y 3118, a new quinolone derivative, rapidly eradicates Listeria monocytogenes from infected mice and L929 cells.

Authors:  T Nichterlein; M Kretschmar; C Budeanu; J Bauer; W Linss; H Hof
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

7.  Comparative in vitro activities of azithromycin, Bay y 3118, levofloxacin, sparfloxacin, and 11 other oral antimicrobial agents against 194 aerobic and anaerobic bite wound isolates.

Authors:  E J Goldstein; C A Nesbit; D M Citron
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.